Pharmacokinetics, safety and immunogenicity of single doses of belatacept administered subcutaneously to healthy subjects

Trial Profile

Pharmacokinetics, safety and immunogenicity of single doses of belatacept administered subcutaneously to healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2016

At a glance

  • Drugs Belatacept; Belatacept
  • Indications Transplant rejection
  • Focus Pharmacokinetics
  • Most Recent Events

    • 29 Sep 2008 Planned number of patients changed from 154 to actual number 47 as reported by ClinicalTrials.gov.
    • 10 Sep 2008 Actual start date changed from Jun 2008 to Aug 2008 as reported by Clinicaltrials.gov.
    • 10 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top